|
Jun 20
|
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
|
|
Jun 20
|
Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
|
|
Jun 20
|
Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet
|
|
Jun 20
|
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
|
|
Jun 20
|
How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl
|
|
Jun 20
|
London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape
|
|
Jun 20
|
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
|
|
Jun 20
|
Ricks Is the King of Pharma, Thanks to Lilly’s Zepbound
|
|
Jun 20
|
LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?
|
|
Jun 20
|
Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand
|
|
Jun 19
|
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
|
|
Jun 18
|
Why Novo Nordisk (NVO) is a Great Dividend Stock Right Now
|
|
Jun 18
|
Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?
|
|
Jun 18
|
GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?
|
|
Jun 18
|
Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock
|
|
Jun 18
|
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
|
|
Jun 18
|
Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes
|
|
Jun 18
|
Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy?
|
|
Jun 18
|
Move Over Hims & Hers Health: This Insurance Business Could Be the Next Monster Healthcare Stock (Hint: It's Not UnitedHealth)
|
|
Jun 17
|
Trump's big beautiful bill: What the pharma industry is watching
|